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RESUMO
Objetivo: Estabelecer a definição, classificação e estadiamento e desenvolver recomen-
dações para o diagnóstico e tratamento da alergia ocular, usando o método Delphi de
consenso.
Métodos: Dez especialistas em alergia ocular da América Latina participaram do painel.
Quatro rodadas de questionários foram respondidas pelos painelistas. Consenso foi
definido quando houve 2/3 ou mais de concordância. Os aspectos principais avaliados
foram: definição, classificação, estadiamento e recomendações para diagnóstico e
tratamento da alergia ocular.
Resultados: “Alergia Ocular” foi proposto como termo geral para descrever as doenças
alérgicas oculares. Consenso sobre classificação não foi atingido. Sinais e sintomas foram
considerados extremamente importantes para o diagnóstico. Consenso foi atingido
sobre a necessidade de se estabelecer um sistema de estadiamento baseado na gravidade
da doença. Controle ambiental e de exposição a alérgenos e o uso de lágrimas artificiais
foram considerados tratamento de primeira linha e o uso tópico de anti-histamínicos,
estabilizadores de membranas de mastócitos e drogas de ação múltipla, como trata-
mento de segunda linha. Anti-inflamatórios não hormonais tópicos e vasoconstrictores
não foram recomendados. Corticosteroides tópicos foram estabelecidos como terceira
linha de tratamento para casos graves de ceratoconjuntivite. Consenso não foi obtido em
relação ao uso sistêmico de corticosteróides e imunossupressores. Abordagem cirúrgica e
tratamentos não convencionais não foram recomendados de rotina.
Conclusão: O desafio de criar recomendações para diversos aspectos da alergia ocular
mostrou-se muito complexo, muitos deles permanencendo ainda controversos. Con-
sensos mais amplos podem ser necessários para melhorar as recomendações atuais
referentes a importantes aspectos da alergia ocular.
Descritores: Questionários; Consenso; Conjuntivite alérgica; Ceratoconjuntivite; Cor-
ticosteroides; Imunossupressores
ABSTRACT
Purpose: To establish current definition, classification and staging, and to deve-
lop diagnosis and treatment recommendations for ocular allergy, by using Delphi
approach.
Methods: Ten Latin American experts on ocular allergy participated in a 4-round
Delphi panel approach. Four surveys were constructed and answered by panelists.
A two-thirds majority was defined as consensus. Definition, classification, staging and
diagnosis and treatment recommendations were the main outcomes.
Results: “Ocular allergy” was proposed as the general term to describe ocular allergic
diseases. Consensus regarding classification was not reached. Signs and symptoms
were considered extremely important for the diagnosis. It was consensus that a
staging system should be proposed based on the disease severity. Environmental
control, avoidance of allergens and the use of artificial tears were recommended as
first line treatment. The secondary treatment should include topical anti-histamines,
mast cell stabilizers and multi actions drugs. Topical non-steroidal anti-inflammatory
and vasoconstrictors were not recommended. Topical corticosteroids were recom-
mended as third line of treatment for the most severe keratoconjunctivitis. Consensus
was not reached regarding the use of systemic corticosteroids or immunosuppressant.
Surgical approach and unconventional treatments were not recommended as routine.
Conclusion: The task of creating guidelines for ocular allergies showed to be very
complex. Many controversial topics remain unsolved. A larger consensus including
experts from different groups around the world may be needed to further improve
the current recommendations for several aspects of ocular allergy.
Keywords: Questionnaires; Consensus; Conjunctivis, allergic; Keratoconjunctivitis;
Adrenal cortex hormones; Immunosuppressive agents
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INTRODUCTION
Allergic conjunctivitis is a term used to describe a highly preva-
lent group of heterogeneous diseases of the ocular surface affec-
ting 20% of the population worldwide(1). It is usually associated with
type I hypersensitivity reaction and the spectrum of clinical expres-
sion varies according to individual cases(1-2). Seasonal allergic con-
junctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal kera-
toconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC) are the
ocular allergic disorders more frequently classified under the de-
nomination of “allergic conjunctivitis”(3). In spite of their different
pathophysiological features, some authors also include other types
of allergy-related reactions, as giant papillary conjunctivitis (GPC),
as part of this group of disease(4).
Clinical evaluation criteria are essential not only for diagnosis,
but also for objective assessment in clinical trials and for clinical
studies on etiological aspects of ocular allergic diseases(5). However,
there have been no internationally established criteria for clinical
evaluation and classification of the severity of ocular allergic diseases.
In the past, the treatment of ocular allergy focused on sympto-
matic relief. More recently, the understanding of the mechanisms
involved in the pathophysiology of this group of diseases has pro-
vided new therapeutic strategies and guidelines(4).
The pharmacologic management of the ocular allergy has been
expanded to specifically address not only the symptomatic relief, but
also signs and symptoms of inflammation associated with the disease(6).
Despite the high prevalence, its definition, a standard classifi-
cation and staging as well as the guidelines to diagnosis and treat-
ment are not globally accepted. In situations where unanimity of
opinions does not exist because of a lack of or contradictory scien-
tific evidences, consensus methods can be useful. A panel of experts
may be an appropriated method to obtain a consensus based on
current knowledge(7-8).
The Delphi panel technique was first proposed in 1946 by RAND
Corporation as a method to collect informations from experts and
to predict future technological capabilities(9). This tool has been ex-
panded to health research to create algorithms of treatment(10-13). In
ophthalmology, it was recently used for establishing a Consensus
on dry eye(8).
In this study, we proposed to establish a consensus on defini-
tion, classification, staging and diagnosis and treatment recommen-
dations for ocular allergy, obtained from a panel of Latin American
experts by using the Delphi approach.
METHODS
The study was designed to acquire knowledge on Ocular Aller-
gy from Latin American ophthalmologists and the Delphi method
was chosen as consensus method.
DELPHI PANEL
Panelists selection
For the selection of the panelists group, some important cha-
racteristics were considered: a) panelists should be diverse in terms
of background; b) representative of the target population; and c) to
have qualification in the area of interest. All the experts invited met
every criteria suggested for the panel selection. Based on these three
requirements, four inclusion criteria were considered for the selec-
tion of panelists:
1. To be willing to answer sets of questionnaires that were sent
in rounds 1 and 2.
2. To be willing to participate on a two day meeting in Orlando
US (round 4).
3. To work as an active licensed ophthalmologist in a Latin Ame-
rican country.
4. To have both local and regional acknowledgement as a cornea
expert confirmed by the actual affliation/position, number of
publications and participation as a speaker in local and inter-
national scientific meetings of the subspecialty.
Ten panelists were selected from 4 different Latin American coun-
tries to compose the panel (Wainsztein R - Argentina; Alves MR,
Freitas D, Sousa LB, Santos MS, and Kandelman S - Brazil; Lozano M -
Colombia; Beltran F, Baca O, and Santacruz C - Mexico).
CONTRACT RESEARCH ORGANIZATION (CRO)
A CRO (Intrials Pesquisa Clínica, São Paulo, Brazil) was selected
to coordinate the deployment of questionnaires, and to work as a
statistical and Delphi method consultant.
PREPARATION OF QUESTIONNAIRES
All questionnaires were based on clinical experience and practi-
ce on the literature on ocular allergy. Rounds of questionnaires were
generated and sent to panelists according to the reached consensus.
The questionnaires were posted on an access-controlled website.
DETERMINATION OF CONSENSUS AND ANALYSIS OF DATA
In order to assure a consistent and robust method for the de-
termination of consensus, a different method of analysis was used
for each kind of question. All statistics were calculated on the
BioStat 3.0 (Sociedade Civil Mamirauá, Brazil).
FACE-TO-FACE MEETING
The panelists had a meeting where the preliminary results of
the previous rounds were presented and discussed. This moment
was formatted also as a round with personal interaction among the
participants.
RESULTS
DEFINITION OF OCULAR ALLERGIC DISEASES
The majority of panelists (>66.67%) agreed that the most ap-
propriated term to describe the allergic diseases of the ocular
surface is “ocular allergy”.
There was also consensus regarding the definition of ocular
allergy. According to the panelists, ocular allergy should be defi-
ned as “an inflammatory disease of the ocular surface, frequently
recurrent, whose basic pathophysiological mechanism is the type I
hypersensitivity, associated or not with other types of hypersen-
sitivity reactions”.
CLASSIFICATION OF OCULAR ALLERGIC DISEASES
Initially, when panelists were surveyed on sub-types of ocular
allergic diseases that should be included in the classification of
ocular allergy, consensus was reached that the following sub-types
should be included: Seasonal conjunctivitis (SAC), Perennial conjunc-
tivitis (PAC), Vernal keratoconjunctivitis (VKC), Atopic keratoconjunc-
tivitis (AKC), and Contact blepharoconjunctivitis (CBC).
At the face-to-face meeting, considering the high level of con-
troversies found in the literature, panelists discussed this topic. It was
decided to repeat this question in a 4th round. Even so, a consensus
was not reached. Half of panelists (5/10) classified the following sub-
types under the term “ocular allergy”: SAC, PAC, VKC, AKC and, in
spite of having different mechanisms, GPC and CBC.
In another topic regarding classification, more than 66.67%
of panelists also agreed that ocular allergic diseases should be
classified, in terms of duration, in acute and chronic and recurrent
forms.
DIAGNOSIS OF OCULAR ALLERGIC DISEASES/DIFFERENTIAL DIAGNOSIS
The panel members agreed that anamnesis, slit-lamp exami-
nation and fluorescein staining are important diagnostic measures
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to detect the ocular surface allergic disease (X2
calc 
< X2
0.05
). There was
also consensus about the importance of signs and symptoms to the
diagnosis (Table 1; Table 2).
Dysfunctional tear syndrome and blepharitis were indicated by
panelists (>66.67%) as the most important conditions that should
be considered in the differential diagnosis of ocular allergies.
STAGING OF OCULAR ALLERGIC DISEASES
Regarding the importance  to establish a staging, the majority
agreed in some degree of importance (>66.67%), especially to
follow patients and to determine algorithms of treatment. They also
recommended that it should be made based on levels of severity,
according to the signs of the disease (X2
calc 
< X2
0.05
).
At the face-to-face meeting, the panel members tried to esta-
blish an appropriated staging based on levels of severity. However,
they did not reach consensus regarding this topic. Therefore, a round
4 was generated to validate the suggestions made during the
meeting. The analysis of the fourth round showed no consensus on
the choice of the best staging criteria for Ocular Allergy. Merely
illustrative, table 3 presents the chosen staging by less than half of
panelists (4/10).
TREATMENT GUIDELINES
The panelists were questioned on the following goals for the
ocular allergy therapy: control of signs and symptoms and tolera-
bility to medications. The degree of importance agreed among the
panelist is presented on table 4.
The panel members (>66.67%) recommended the environmen-
tal control and the need to avoid contact with known allergens as
primary interventions that should be used as part of first-line step
for the treatment of ocular allergy.
Artificial tears
The majority of panelists (>66.67%) answered that they always use
topical lubricants for treating ocular allergy. Three remnant panelists
indicated topical lubricants only for some chronic cases and for acute
crisis. When asked about for how long, most of them (9 of 10) agreed
that they should be used indefinitely. It was also consensus that pre-
servative free artificial tears should be prescribed (>66.67%).
Anti-histamines
The majority of panel members (80%) agreed that topical anti-
histamines are indicated only in the treatment of acute cases of
ocular allergy and for a short period (less than 4 weeks) of time.
Mast cells stabilizers
Panelists reached consensus during the first round of questions,
and at the face-to-face meeting they unanimously agreed (100%)
that topical mast cells stabilizers are extremely important and should
be always used in the treatment of ocular allergic patients during
an undefined period of time.
Multiple action drugs (MAD)
When panel members were surveyed on the importance of the
use of topical multiple action (anti-histamine, mast cell stabilizer and
anti-inflammatory actions) drugs, consensus was reached (>66.67%)
that they are extremely important for ocular allergy treatment.
During the face-to-face meeting, panelists recommend a “once a
day use” as being desirable for these drugs.
Topical vasoconstrictor
The majority of panelists (80%) did not recommend topical vaso-
constrictors for the treatment of ocular allergic patients.
Topical non-steroidal anti-inflammatory drugs (NSAID)
When panelists were inquired about their opinions regarding
the use of topical NSAID in the treatment of ocular allergic patients,
90% of them agreed that it is not important, thus, they should not be
recommended.
Topical corticosteroids
Even though more than half of panelists (6 of 10) agreed on the
use of topical corticosteroids as an important choice for treating
some chronic cases and acute crises of ocular allergy, no consensus
was reached on this issue. However, during the face-to-face mee-
ting, panel members (<66.67%) made some recommendations re-
garding the indications of this class of drugs. Considering the known
treatment-related ocular adverse events with the use of topical
corticosteroids, the panel agreed that they should not be used as
first option treatment in the majority of ocular allergy cases. The
panel also recommended the use of “weak topical corticosteroids”
for treating specific cases, for a short period of time (less than 2
weeks), always considering the intensity of the acute crisis; and
“strong corticosteroids”, for treating acute crisis, also during a short
period of time (from 2 to 4 weeks).
 Table 1. Most important signs for ocular allergy diagnosis*
Signs Level of importance
Papillary hypertrophy of superior tarsal Extremely important
Diffuse conjunctival papillary hypertrophy Extremely important
Shield ulcer Extremely important
Limbal edema Extremely important
*= Cronbach alpha=0.7
Table 2. Most important symptoms for ocular allergy diagnosis**
Symptoms Level of importance
Itching Extremely important
Tearing Very important
Mucous discharge Very important
Edema Very important
**= Cronbach alpha=0.8
Table 3. Staging of ocular allergy severity
Grade/Level Papilla Conjunctiva Cornea Limbus
1 Micro: < 0,5 mm Hyperemia (-) (-)
2 Micro: < 0,5 mm Hyperemia Sectorial SPK Limbitis in 1 quadrant
3 Macro: > 0,5 mm - 1 mm Hyperemia and edema Diffuse SPK Limbitis in 2 quadrants
4 Giants: > 1 mm Hyperemia, edema and scar Ulcer Limbitis in 3 or more quadrants
SPK= superficial punctate keratitis
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Topical immunomodulator
When asked about the need of to use topical immunomodu-
lator for controlling signs and symptoms in ocular allergic patients,
90% of panelists answered that they never indicated this class of
medication.
Systemic corticosteroids & immunomodulator/immunosuppression
Regarding the use of systemic treatment with corticosteroids
or immunomodulator/immunosuppressant, no consensus was
achieved on its use. Half of panelists indicate the use of these
medications only for some severe cases of chronic allergic kera-
toconjunctivitis and the other half of them never use this systemic
treatment for any type of ocular allergies.
Surgical treatment
Consensus was reached on indications of surgical treatment of
ocular allergic patients. Eighty percent of panelists did not indicate
any kind of surgery for treating ocular allergy. At the face-to-face
meeting, panelists made some comments regarding this topic and
agreed that surgical treatment may be indicated in very specific cases
or in the presence of complications, and that it should be considered
as ultimate treatment option for the most severe cases.
Unconventional treatment
During the face-to-face meeting, panelists discussed on indica-
tions of unconventional treatment, such us vaccine, homeopathies
and acupuncture. They did not recommend these therapies for
ocular allergy therapy.
DISCUSSION
A variety of scientific methods are used in scientific studies for
consensus procedures, as Nominal Group, NIH Consensus Develop-
ment, and Delphi Panel(12). From all these, the Delphi Panel method
is the most used in health field with more patterns described and
standardized(13).
There is no general agreement in the literature that defines
specific criteria to determine when consensus has been achieved,
or the best statistical method to use for responses analysis(10-11). The
proposed analytical process performed in this study had the objec-
tive to ensure maximum validity of the results in Delphi methodo-
logy and improved evidence decisions achieved.
A result obtained from the panel was the recommendation of
changing the term “allergic conjunctivitis”, commonly used to deno-
minate all ocular allergic disorders, to “ocular allergy”. Ocular allergy
seems to be a broad and more appropriated term to describe this
group of heterogeneous diseases, whose basic mechanism is allergic,
including conjunctivitis and keratoconjunctivitis.
Different classifications of the ocular allergic diseases have
been proposed in the literature(3,14-16). Recently, the International
Ocular Inflammation Society proposed a classification based on the
type of immune response, dividing the ocular allergic conditions
into 3 groups: IgE-mediated (SAC/PAC), IgE and non IgE-mediated
(VKC/AKC) and non IgE-mediated (GPC/CBC)(16).
Panelists discussed on different immunopathogenetic mecha-
nisms involved in the various types of ocular allergies and the wide
variety of clinical features of these diseases as well, as important
issues that difficult the establishment of an appropriated classi-
fication. Although a consensus regarding this topic has not been
reached, half of panelists suggested the inclusion of Seasonal and
Perennial allergic conjunctivitis, Vernal and Atopic keratoconjunc-
tivitis, Giant papillary conjunctivitis and Contact blepharoconjunc-
tivitis under the term “Ocular allergy”.
Consensus was reached on the significance of establishing a
staging of ocular allergic diseases based on levels of severity. Such
staging would allow appropriated evaluation of progression, the
establishment of algorithms of treatment, as well as objective assess-
ment in clinical trials for analysis of treatment efficacy(5).
During the meeting, some general staging applicable to all
types of ocular allergy were proposed. However, panelists did not
consensually agree on any suggested staging. A possible reason for
this is the difficult of effectively evaluating the severity of different
diseases together with all of their diverse clinical features. Thus,
panelists are in agreement that staging of specific types of ocular
allergic diseases are recommended, as those recently published
based on severity of signs and symptoms of VKC(17) and AKC(18).
Advances in the understanding of ocular allergic disorders
mechanisms have provided foundation for more rational guideli-
nes of treatment of these diseases. The goals of therapy should
include not only the control of signs and symptoms, but also
improvement of ocular health of patients with ocular allergies(2,4,6,19).
Panelists suggested measures including environmental control and
avoidance of allergens, which might be achieved by removing
allergens source or changing occupational venue, as first line treat-
ment. Another recommendation was the use of artificial tears for all
cases of ocular allergies, aiming at either the removal and dilution
of allergens or the reestablishment of the tear film, which can be
compromised by ocular surface inflammation produced by the
allergic response.
The panel recommended that the secondary treatment should
include the use of topical anti-histamines, mast cell stabilizers and
multi actions drugs, as measures of symptomatic control. Despite
some clinical studies showing improvement of symptoms with its
use in patients with SAC, topical non-steroidal anti-inflammatory
drugs were not recommended(20).
The third line of treatment should be indicated for the most
severe cases of keratoconjunctivitis, when topical medications
failed in controlling allergic signs and symptoms. Panelists indica-
ted the rational use of topical corticosteroids for treating some
chronic cases and acute crises, considering a short time course of
treatment and its ocular side effects. Although there are clinical trials
showing that topical cyclosporine A might aid in the control of VKC
and AKC patients(21-22), most of panelists did not indicate topical immu-
nomodulator as routine to treat ocular allergies. They discussed on
the need of high concentrations of the drug and the low tolera-
bility to the available vehicles as limiting factors for its use.
Regarding the surgical approach, panelists in general contra-
indicated its use for any case of ocular allergy. However, after dis-
cussing during the face-to-face meeting, they suggested to con-
sider such treatment in extremely severe cases for treating corneal
complications, such as persistent and unresponsive to conventional
treatment keratitis and very recurrent shield ulcer. Some publica-
tions have reported good results with the surgical removal of giant
papillae from superior tarsal conjunctiva associated with several
techniques, such as mucous membrane graft, for treating corneal
complications in patients with VKC(23-24). However, there is still a lack
of evidence-based results that indicate rationality for their use. For
Table 4. Goals for ocular allergy therapy*
Symptoms Level of importance (Likert scale result)
Symptoms control Extremely important
Signs improvement Extremely important
Tolerability Extremely important
Quality of life Extremely important
Time of action Extremely important
Cost Very important
Visual acuity improvement Very important
*= Cronbach alpha=0.9
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this same reason, panelists answered that they did not indicate
unconventional treatment, such us vaccine, homeopathies and acu-
puncture for treating ocular allergies.
The task of creating guidelines for ocular allergies showed to
be very complex. Thus, a larger consensus including experts from
different groups around the world may be needed to further
improve many controversial topics, especially an internationally
acceptable classification and staging and a more rationale algo-
rithm of treatment for this challenger group of diseases.
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